EPISODE · Jul 7, 2025 · 9 MIN
Adam Mendelsohn - CEO & Co-Founder Vivani Medical at BIO Boston 2025
from The BioHub: The Top Voices in Biotech · host Max Brennan - Biotech HeadHunter
From BIO Boston: Adam Mendelsohn, CEO of Vivani MedicalIn this episode, I sit down with Adam Mendelsohn — bioengineer turned biotech CEO — and the co-founder of Vivani Medical.What started in a university basement has grown into a publicly listed company tackling one of the biggest challenges in healthcare: medication adherence.We talk about:— Building a biotech from scratch, and staying alive in tough times— Why GLP-1 implants could transform obesity and diabetes care— The mindset behind navigating clinical milestones and setbacks— And how Vivani’s platform could reshape drug delivery entirelyAdam’s story is full of grit, clarity, and ambition — and Vivani is just getting started.This episode is part of a series of in-person interviews from BIO Boston with some of the sharpest leaders in the industry.More to come.
What this episode covers
From BIO Boston: Adam Mendelsohn, CEO of Vivani MedicalIn this episode, I sit down with Adam Mendelsohn — bioengineer turned biotech CEO — and the co-founder of Vivani Medical.What started in a university basement has grown into a publicly listed company tackling one of the biggest challenges in healthcare: medication adherence.We talk about:— Building a biotech from scratch, and staying alive in tough times— Why GLP-1 implants could transform obesity and diabetes care— The mindset behind navigating clinical milestones and setbacks— And how Vivani’s platform could reshape drug delivery entirelyAdam’s story is full of grit, clarity, and ambition — and Vivani is just getting started.This episode is part of a series of in-person interviews from BIO Boston with some of the sharpest leaders in the industry.More to come.
NOW PLAYING
Adam Mendelsohn - CEO & Co-Founder Vivani Medical at BIO Boston 2025
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m